Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
5(83.3%)
Phase 3
1(16.7%)
6Total
N/A(5)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT02425514Not ApplicableCompleted

Evaluation of Bone Union Following Anterior Cervical Fusion Using a NovoMax™

Role: lead

NCT03532945Not ApplicableCompleted

A Follow-up Study to Evaluate the Efficacy and Safety of Novomax in Posterior Lumbar Interbody Fusion

Role: lead

NCT02714829Not ApplicableCompleted

Clinical Study of Injectable Ceramics Bone Graft Substitute Containing rhBMP-2

Role: lead

NCT02504242Phase 3Unknown

A Multi-center, Comparative Clinical Trial to Evaluate the Efficacy and Safety of Inject BMP in Patients Undergoing Transforaminal Lumbar Interbody Fusion

Role: lead

NCT01764906Not ApplicableUnknown

The Clinical Study of Novosis in Posterolateral Fusion

Role: lead

NCT01439464Not ApplicableUnknown

Study of Bioactive Glass-ceramic Intervertebral Spacer (Bonglass-SS) in Posterior Lumbar Interbody Fusion

Role: lead

All 6 trials loaded